1. |
Mollan SP, Aguiar M, Evison F, et al. The expanding burden of idiopathic intracranial hypertension[J]. Eye (Lond), 2019, 33(3): 478-485. DOI: 10.1038/s41433-018-0238-5.
|
2. |
Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients[J]. Brain, 1991, 114 (Pt 1A): 155-180.
|
3. |
Mitchell C, Mathew S, Harris A, et al. Etiology, pathogenesis and management of idiopathic intracranial hypertension, and role of optic canal size in asymmetric papilledema: a review[J]. Eur J Ophthalmol, 2021, 31(3): 892-903. DOI: 10.1177/11206721211005709.
|
4. |
Bidot S, Bruce BB, Saindane AM, et al. Asymmetric papilledema in idiopathic intracranial hypertension[J]. J Neuroophthalmol, 2015, 35(1): 31-36. DOI: 10.1097/WNO.0000000000000205.
|
5. |
李梓敬, 蓝育青, 廖韵如, 等. 视盘血管炎的临床特征分析[J]. 中山大学学报(医学版), 2018, 38(2): 258-262. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2018.0039.Li ZJ, Lan YQ, Liao YR, et al. Clinical characteristics of optic disc vasculitis[J]. Journal of Sun Yat-sen University (Medical Sciences), 2018, 38(2): 258-262. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2018.0039.
|
6. |
NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall M, McDermott MP, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial[J]. JAMA, 2014, 311(16): 1641-1651. DOI: 10.1001/jama.2014.3312.
|